Golden Green’s Inovio Pharmaceuticals INO Stock Holding History

Golden Green’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,052	Closed	-$340K	–	168
2021 Q1	$340K	Buy	3,052 +2,142	+235%	+$282K	0.29%	122
2020 Q4	$97K	Buy	+910	New	+$121K	0.09%	119

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Golden Green's INO Position: Q2 2021 in Review

Golden Green sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 3,052 shares — an estimated $340K sold.

Golden Green first reported a position in INO in Q4 2020 and held it in 2 quarters. The position peaked at $340K in Q1 2021. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

Golden Green reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Golden Green sold 3,052 Inovio Pharmaceuticals shares in Q2 2021, an estimated $340K.
Golden Green first reported a position in Inovio Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Golden Green's Inovio Pharmaceuticals position peaked at $340K in Q1 2021.
211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on Golden Green's 13F filing for Q2 2021, filed 14 Jul 2021.